论文部分内容阅读
(接2月下)此外,JCAD研究的平均随访期较IONA研究更长,两者分别为2.7和1.6年;I O N A中安慰剂组及J C A D中对照组的全因死亡率分别是129/2561例(5.0%)和156/2,558例(6.1%)。JCAD研究较IONA研究更高死亡率,其原因可能是IHD研究更加严格以及观测时间更长。IONA研究的亚组分析也表明,尼可地尔对治疗服用更多抗心绞痛药物的高危患者,或是对更高的加拿大心血管协会(CCS)功能状态评分患者,能起到最大降低绝对风险的作用。
(Followed by 2 months). In addition, the average follow-up of the JCAD study was longer than the IONA study, which was 2.7 and 1.6 years respectively; allogeneic mortality in the IONA placebo group and the JCAD control group was 129/2561 (5.0%) and 156 / 2,558 cases (6.1%). The JCAD study reported a higher mortality rate than IONA, probably due to stricter IHD studies and longer observation times. A subgroup analysis of the IONA study also showed that nicorandil can be used to minimize absolute risk for high-risk patients who are on treatment for more anti-anginal drugs or for patients with higher functional status scores from the Canadian Cardiovascular Association (CCS) Role.